HALIFAX, Nova Scotia–(BUSINESS WIRE)–CUPE support staff who work in long-term care, their co-workers, and friends, will hold rallies across the province as part of a “Day of Action” on Monday, June 27, calling on the government to increase wages for support staff too. Rallies will take place across the province from 11 am to 1 … [Read more…]
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the … [Read more…]
Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial Zeposia was well tolerated, with more than 80% of people staying … [Read more…]
Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria Data are among five … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028″ gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of prostate cancer, NETs, Lung cancer, solid tumors and other … [Read more…]
— Data being presented at the European Academy of Neurology Congress demonstrates consistent reductions in NMOSD attacks and disability scores across populations — DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced new findings from a post hoc analysis of the N-MOmentum Phase 3 pivotal trial of UPLIZNA supporting the medicine’s efficacy in Europeans living with … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Specialty Drug Distribution Market Research Report by Indication (AIDS, Hemophilia, and Multiple Sclerosis), Type, Distribution Type, Distribution Channel, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The United States Specialty Drug Distribution Market size was estimated at USD 340.41 million in 2021 … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Body Contouring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global body contouring market reached a value of $7.3 Billion in 2021. Looking forward, the publisher expects the market to reach $11.1 Billion by 2027, exhibiting a CAGR of 6.9% during 2022-2027. … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Urethral Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Urethral Cancer The pipeline guide reviews pipeline therapeutics for Urethral Cancer by companies and universities/research institutes based on … [Read more…]
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease. The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 … [Read more…]
